Evaluating AI vendors in healthcare, on the record.

The AI Health Index reads this as a choice about how much of the work a health system wants its vendor to perform, because both platforms are the data foundation an organisation buys to run risk contracts. Arcadia has stayed a data and analytics company: integration across more than fifty electronic health record systems resolved through its own master patient index, Medicare claims benchmarks with the provenance named, and validation from the National Committee for Quality Assurance that data flowing through the platform is fit to be scored on, with its first generative product only now arriving. Innovaccer is becoming an operator: five acquisitions have added live health coaches, revenue cycle services and payer utilisation management, and the Centers for Medicare and Medicaid Services has accepted it as a participant in a federal care model rather than only a supplier to participants. Choose Arcadia where the requirement is a validated data foundation and the buyer brings or builds the intelligence on top. Choose Innovaccer where breadth and current independent validation decide, provided the buyer establishes which capabilities are production proven in its own setting. Neither publishes a price, names a base model, or publishes any bias testing. One thing a buyer should know: the documented failure mode in claims based risk scoring is silent, a patient scored too low is simply never contacted and no incident ever surfaces, so the one question to ask both vendors is what the risk models predict and whether subgroup performance has been measured.

The AI Health Index reads this as a choice between scope and verification rather than between two versions of the same product, because both return a cited clinical answer at the point of care and a clinician choosing one is not choosing the other. Glass Health generates a ranked differential with suggested workups, drafts the assessment and plan, answers questions across an index of more than 38 million peer reviewed articles, and documents the visit through ambient scribing, which Vera Health does not attempt. Vera Health does one thing, retrieval first evidence search across more than 60 million papers, guidelines and care pathways, and surrounds it with the strongest HIPAA posture in this segment, the published, dated full text of its business associate agreement. Glass Health carries the independent evidence, placing among the top medical AI systems in the Harvard and Stanford ARISE NOHARM physician validated benchmark, while every performance figure Vera Health publishes about itself is vendor run. Choose Glass Health for reasoning and documentation in one product, provided the buyer runs the security and residency diligence Glass Health has not published answers to. Choose Vera Health where cost and contracting decide. Neither names the model behind its answers, and neither publishes a bias or subgroup analysis of its generative layer. One thing a buyer should know: both products can be adopted by an individual clinician with no procurement conversation, so the moment where a compliance team asks where patient data goes never arrives on its own, and the clinician who signs up carries that question personally.

Both answer the same clinical question at the same moment. The split is what the answer is grounded in and who pays for it. If your failure mode is a fluent answer built on real citations with faulty reasoning behind them, the independent literature documents precisely that in OpenEvidence: accurate citations, interpretive errors. If your failure mode is an authoritative answer inheriting the blind spots of a single editorial tradition, that is UpToDate's structural exposure, and it publishes no evaluation output to bound it. OpenEvidence is free, funded by pharmaceutical and device advertising, and United States only since April 2026. UpToDate is subscription funded, openly priced at the individual tier, and sold in more than thirty countries. Start with UpToDate if oversight design decides it, OpenEvidence if literature breadth and cost do.